SOLICITATION NOTICE
A -- Maintenance of the NHLBI Biologic Specimen Repository
- Notice Date
- 12/29/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-HB-2016-03-JT
- Archive Date
- 5/1/2015
- Point of Contact
- John Turner, Phone: 3014029787, Janet Mattson, Phone: 3014350357
- E-Mail Address
-
john.turner@nih.gov, janet.mattson@nih.gov
(john.turner@nih.gov, janet.mattson@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Heart, Lung, and Blood Institute anticipates the issuance of a request for proposal (NHLBI-CSB-HB-2016-03-JT) on or about January 12, 2015, on behalf of the Division of Blood Diseases and Resources (DBDR). The requirement is to efficiently maintain, acquire and distribute quality and scientifically valuable biospecimens from NHLBI-funded clinical studies. Biospecimen material types include serum, plasma, whole blood, peripheral blood mononuclear cells, immortalized cell lines, tissue and other bodily fluids or substances such as bronchial lavage, urine, biopsy materials, whole blood spots dried on filter paper and embedded tissue blocks. Background: The National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) conducts and supports epidemiological and clinical research in heart, lung and blood diseases and transfusion medicine. The NHLBI Biologic Specimen Repository (Biorepository), first funded in 1980, is a storage and management program for biospecimens collected on selected NHLBI clinical studies. The Biorepository was initially established to support the need for archival collections to address emerging blood-safety concerns. These collections have made several seminal contributions to public health, such as establishing the viral origin of the agent responsible for non-A, non-B hepatitis (HCV) and transfusion transmissibility of HIV. Towards the end of the 1990s the Biorepository mission was expanded to acquire biospecimens from studies with unique patient populations, such as the Honolulu Heart Program, A Case Controlled Etiologic Study of Sarcoidosis, and the Multicenter Hemophilia Cohort Study. These richly phenotyped biospecimens provide a return on the original study investment through their continued research use. Access to the biospecimens is provided through the Biologic Specimen and Data Repositories Information Coordinating Center (BioLINCC). BioLINCC, funded under contract HHSN268201400014C, maintains the clinical study datasets in the NHLBI Data Repository, links the study datasets in the Data Repository to their biospecimens in the Biorepository, and makes both resources available online through the BioLINCC website at www.biolincc.nhlbi.nih.gov. The management of the Biorepository follows the current National Cancer Institute (NCI, http://biospecimens.cancer.gov/bestpractices/) and International Society for Biological and Environmental Repositories (ISBER; (http://www.isber.org/?page=BPR) Best Practices. In addition, a five-year Business Plan is used to assist in long term planning. The Plan has three goals: 1) increase use; 2) acquire new collections with potential scientific utility; and 3) minimize infrastructure costs Plan activities are guided by a NHLBI trans-Division committee and coordinated by BioLINCC in collaboration with the Biorepository. Currently, 4.1 million vials from 66 clinical studies are housed in 163 mechanical freezers (28 upright; 123 chest) and 9 liquid nitrogen freezers. Contemporary study collection vials are labeled with barcoded labels that may include a study ID or a laboratory ID and the stored material type. Vial labels from older studies may be barcoded, printed or handwritten and may contain subject initials and other sensitive data. The biospecimen inventory is managed using the Biological Specimen Inventory System (BSI) software (http://www.bsisystems.com/). Each vial has a record in the BSI and BioLINCC maintains a direct link to the Biorepository BSI software to enable real-time searching for biospecimens within and across study collections. The number of new biospecimens that will be acquired during the contract is not known but the total inventory at the end of the contract is unlikely to exceed ten million samples. The current five-year contract with Precision Bioservices, Inc., (contract number HHSN268201400035C) will expire on April 30, 2016. Purpose and Objectives: The objective of this contract is to meet the goals of the Business Plan in a cost-effective manner by implementing strategies to efficiently maintain, acquire and distribute quality and scientifically valuable biospecimens from NHLBI-funded clinical studies. Biospecimen material types include serum, plasma, whole blood, peripheral blood mononuclear cells, immortalized cell lines, tissue and other bodily fluids or substances such as bronchial lavage, urine, biopsy materials, whole blood spots dried on filter paper and embedded tissue blocks. The specimens have been collected over many years from carefully chosen subjects and reflect the history of the NHLBI epidemiology and clinical trials programs since 1965. Biospecimens are typically received as bulk relocations at the end of the clinical study. Some intermittent shipping from ongoing studies may occur as the need arises. Biospecimens that are limited in number and/or volume are divided into multiple vials or sections or expanded, depending on material type. Biospecimens are requested online through the BioLINCC program and Biorepository staff assist with the online review of each request and provide recommendations regarding the appropriateness of the material type and volume of material requested. Biorepository staff also assist in reviewing the suitability of collections for transfer to the Biorepository and in developing strategies to extend limited resources and reduce the number of vials identified as having low scientific utility. The procedures to acquire and distribute biospecimens are available online at www.biolincc.nhlbi.nih.gov in the BioLINCC Handbook. This announcement is not a request for proposal (RFP): This announcement is not a RFP and, although one award is anticipated, the Government is not committed to award a contract pursuant to this announcement. The Government intends to award one (1) Indefinite Delivery/Indefinite Quantity (IDIQ) contract with an ordering period of five years with an approximate effective date of February 1, 2016. It is anticipated that an annual Task Order will be awarded to fully fund twelve-months of administrative effort to maintain the Biorepository infrastructure. Additional Task Orders to acquire, distribute and cull historic collections will be funded as needed over the period of performance. Task Orders will be on a Cost-Reimbursement basis, expect when a Firm-Fixed-Price contract type is more appropriate.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-HB-2016-03-JT/listing.html)
- Place of Performance
- Address: The Request for Proposal will contain a mandatory qualification criterion which restricts the facility to be located within the continental United States to accommodate the requirements for shipping of biological specimens to and from the facility., United States
- Record
- SN03605373-W 20141231/141229233933-cdfb918e319221ddfcd0010521c141bf (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |